Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Cogent Biosciences (COGT) Assets Average (2018 - 2026)

Cogent Biosciences' Assets Average history spans 9 years, with the latest figure at $920.3 million for Q1 2026.

  • Quarterly Assets Average rose 200.9% to $920.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $920.3 million through Mar 2026, up 200.9% year-over-year, with the annual reading at $632.8 million for FY2025, 97.32% up from the prior year.
  • Assets Average came in at $920.3 million for Q1 2026, up from $681.8 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $920.3 million in Q1 2026 to a low of $219.5 million in Q1 2022.
  • The 5-year median for Assets Average is $348.8 million (2022), against an average of $390.4 million.
  • Year-over-year, Assets Average tumbled 38.35% in 2025 and then soared 200.9% in 2026.
  • Cogent Biosciences' Assets Average stood at $316.2 million in 2022, then increased by 5.77% to $334.4 million in 2023, then rose by 6.43% to $356.0 million in 2024, then skyrocketed by 91.53% to $681.8 million in 2025, then surged by 34.99% to $920.3 million in 2026.
  • Per Business Quant, the three most recent readings for COGT's Assets Average are $920.3 million (Q1 2026), $681.8 million (Q4 2025), and $350.4 million (Q3 2025).